VolitionRx Limited Pre-Pays $7.5 Million Note Early

VolitionRx Limited, a multinational epigenetics company, has announced the full pre-payment of a $7.5 million senior secured convertible promissory note, issued to Lind Global Asset Management XII LLC, more than eight months ahead of its originally scheduled maturity date. The company has satisfied all obligations under the note, which was due on May 20, 2027.

Cameron Reynolds, Volition’s Chief Executive Officer, expressed satisfaction with the early payment.

The pre-payment is part of Volition’s ongoing efforts to improve its financial position and reduce debt and expenses. The company remains committed to maximizing stockholder value. As of the announcement, the senior secured convertible promissory note, dated January 7, 2026, in the original principal amount of $2,400,000, remains outstanding, with a balance of $2,041,667.

Volition, headquartered in Henderson, Nevada, is focused on advancing the science of epigenetics. The company aims to save lives and improve outcomes for people and animals with life-altering diseases through earlier detection and disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.

The company’s commitment to reducing its financial obligations aligns with its broader strategic goals.

This action underscores Volition’s proactive approach to managing its financial health and maintaining transparency with its stakeholders.